Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 19/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495481 | 1.00 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1546106 | 0.90 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1546641 | 0.89 | ADORA2B (0.56) | ADORA2BADORA2AADORA3ADORA1SCD5 | |
| SCHEMBL8979404 | 0.88 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1546614 | 0.87 | ADORA2B (0.59) | ADORA2BADORA2AADORA3ADORA1SCD5 | |
| SCHEMBL5541331 | 0.87 | ADORA2B (0.45) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1723697 | 0.87 | ADORA2B (0.52) | ADORA2BADORA2AADORA3ADORA1RPS6KA3 | |
| SCHEMBL1546107 | 0.87 | ADORA2B (0.54) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL244147 | 0.86 | ADORA2B (0.55) | ADORA2BADORA2AADORA3ADORA1PLK4 | |
| SCHEMBL1546781 | 0.85 | KLKB1 (0.52) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685132-B1 | Processes and intermediates for the preparation of purine derivatives useful in the treatment of (inter alia) cancer, asthma and diarrhea | GILEAD SCIENCES INC (US) | 2012-08-29 | — | — | EP | claimed |
| US-20090137802-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. | 2009-05-28 | — | — | US | claimed |
| US-7521554-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2009-04-21 | — | — | US | claimed |
| JP-2007512335-A | — | — | 2007-05-17 | — | — | JP | claimed |
| US-20060281921-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | claimed |
| EP-1685132-A1 | A sb 2B /sb ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-08-02 | — | — | EP | claimed |
| WO-2005051951-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | claimed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| CN-111770926-A | Tricyclic compounds, compositions and medical uses thereof | 因佩蒂斯生物科学有限公司 | 2020-10-13 | — | — | CN | disclosed |
| US-8940751-B2 | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-01-27 | — | — | US | disclosed |
| US-8940751-B2 | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-01-27 | — | — | US | disclosed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006044610-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2005051951-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137802-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2B 3/4885ADORA2A 1/4885ADORA3 4/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA2A 1/4885ADORA3 2/4885 |
| US-20060281921-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.